Among 291 patients with residual disease after neoadjuvant therapy, the distribution of breast cancer phenotype was: HR-positive/HER2-negative 35.7% (n = 104), triple-negative 32% (n = 93) and HER2-positive 32.3% (n = 94; HER2-positive/HR-positive, n = 66; HER2-positive/HR-negative, n = 28). Here, ERBB2 is linked to breast carcinoma.